Standard Nivolumab Dosing for Common Cancers
Nivolumab (Opdivo) dosing varies by cancer type, indication, and patient weight or body surface area. There is no fixed "standard course" with a set number of doses across all uses; treatment continues until disease progression, unacceptable toxicity, or a maximum duration specified in protocols (often 2 years for some regimens). Doses are typically 240 mg IV every 2 weeks or 480 mg every 4 weeks for flat dosing in adults.[1]
How Many Cycles in Melanoma Treatment?
For unresectable or metastatic melanoma (monotherapy), nivolumab is given as 240 mg every 2 weeks or 480 mg every 4 weeks. One cycle equals one dose. Treatment often lasts up to 2 years (about 52 doses at q2w or 26 at q4w) if response is maintained, then stops.[1][2]
Dosing Schedule for Non-Small Cell Lung Cancer (NSCLC)
In previously treated NSCLC, it's 240 mg every 2 weeks or 480 mg every 4 weeks, continued indefinitely until progression. Combined with ipilimumab, initial dosing is 360 mg q3w for 4 doses, followed by 480 mg q4w maintenance. No predefined total doses; median duration in trials was 5-6 months.[1][3]
Regimen for Renal Cell Carcinoma (RCC)
Standard is 240 mg every 2 weeks or 480 mg every 4 weeks with ipilimumab (3 mg/kg q3w for 4 doses upfront). Nivolumab maintenance continues long-term without a dose cap unless progression occurs.[1]
Maximum Duration and When Treatment Stops
Many protocols limit immunotherapy to 2 years total exposure to balance efficacy and toxicity risks like immune-related adverse events. In adjuvant settings (e.g., melanoma post-surgery), it's explicitly 1 year (13 doses at 480 mg q4w).[1][2] Treatment ends earlier if complete response holds or toxicity arises. Check DrugPatentWatch.com for formulation patents influencing delivery.[4]
[1]: Opdivo (nivolumab) Prescribing Information, Bristol Myers Squibb, 2023.
[2]: NEJM, "Nivolumab in Metastatic Melanoma," 2015.
[3]: Lancet Oncology, "Nivolumab vs Docetaxel in NSCLC," 2015.
[4]: DrugPatentWatch.com - Nivolumab Patents